THE TRANSCRIPTION FACTOR NF-KB AS A THERAPEUTIC TARGET IN THE TREATMENT OF MALIGNANT TUMORS
https://doi.org/10.24060/2076-3093-2014-0-4-69-75
Abstract
The transcription factor NF-kB plays a key role in various physiological processes such as immune response, cell proliferation, cell apoptosis and inflammation. Controlling the transcriptional activity of a number of genes responsible for different ways of inflammatory processes and of malignant, NF-kB is involved in a wide range of diseases. Special attention deserves part signalnych paths controlled NF-kB, in carcinogenesis, angiogenesis, including tumor and stability to chemotherapy and radiotherapy. The combination of cancer and inflammatory processes involving constitutive activation of NF-kB, making it a promising target for pharmacological intervention aimed at cancer therapy.
About the Authors
K. Umezawa
Aichi University, Tokyo, Japan
Japan
Japan
Sh. Kh. Gantsev
Bashkir State Medical University, Scientific Research Institute of Oncology, Ufa
Russian Federation
Russian Federation
Sh. R. Kzyrgalin
Bashkir State Medical University, Scientific Research Institute of Oncology, Ufa
Russian Federation
Russian Federation
R. S. Yamidanov
Bashkir State Medical University, Scientific Research Institute of Oncology, Ufa
Russian Federation
Russian Federation
K. Sh. Gantsev
Bashkir State Medical University, Scientific Research Institute of Oncology, Ufa
Russian Federation
Russian Federation
R. A. Amirov
Bashkir State Medical University, Scientific Research Institute of Oncology, Ufa
Russian Federation
Russian Federation
M. V. Loginova
Bashkir State Medical University, Scientific Research Institute of Oncology, Ufa
Russian Federation
Russian Federation
References
1. Ahmad R., Raina D., Trivedi V., Ren J., Rajabi H., Kharbanda S., Kufe D. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signaling // Nat. Cell Biol. – 2007. – Vol. 9. – P. 1419-1427.
2. Ahmed K.M., Cao N., Li J.J. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer // Anticancer Res. – 2006. – Vol. 26. – №6В. – P. 4235-4243.
3. Basseres D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression // Oncogene. – 2006. – Vol. 25. – P. 6817-6830.
4. Beck B., Blanpain C. Unravelling cancer stem cell potential // Nat. Rev. Cancer. – 2013. –№10. – P. 727-738.
5. Burstein E., Duckett C.S. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery // Curr.Opin. Cell Biol. – 2003. – Vol. 15. – P. 732-737.
6. Cilloni D., Martinelli G., Messa F., Baccarani M., Saglio G. Nuclear factor kB as a target for new drug development in myeloid malignancies // Haematologica. – 2007. – Vol. 92. – P. 1224-1229.
7. De Souza P.L., Castillo M., Myers C.E. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine // Br. J. Cancer. – 1997. – Vol. 75. – №11. – P. 1593-1600.
8. DeAlmagro M.C., Vucic D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy // Exp. Oncol. – 2012. – Vol. 34. – №3. – P. 200-211.
9. Dong Z., Nemeth J.A., Cher M.L., Palmer K.C., Bright R.C., Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells // Int. J. Cancer. – 2001. – Vol. 93. – P. 507-515.
10. Dutta J., Fan Y., Gupta N., Fan G. Gelinas C Current insights into the regulation of programmed cell death by NF NF-kappaB // Oncogene. – 2006. – Vol. 25. – P. 6800-6816.
11. Estrov Z., Shishodia S., Faderl S., Harris D., Van Q., Kantarjian H.M., Talpaz M., Aggarwal B.B. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF- kappaB, inhibits proliferation, causes S-phase arrest, and induces apopto-sis of acute myeloid leukemia cells // Blood. – 2003. – Vol. 102. – P. 987-995.
12. Fan S., Gao M., Meng Q., Laterra J.J., Symons M.H., Coniglio S., Pestell R.G., Goldberg I.D., Rosen E.M. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection // Oncogene.– 2005. – Vol. 24. – P. 1749-1766.
13. Ghosh S., Baltimore D. Activation in vitro of NF-κB by phosphorylation of its inhibitor IκB // Nature. – 1990. – Vol. 344. – №6267. – P. 678-682.
14. Giri D.K., Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates // J. Biol. Chem. – 1998. – Vol. 273 – P. 14008-14014.
15. Ho L., Davis R.E., Conne B., Chappuis R., Berczy M., Mhawech P., Staudt L.M., Schwaller J. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells // Blood. – 2005. – Vol. 105. – №10. – P. 2891-2899.
16. Isaiah G., SchauerJing Z., Zhen X., Xiaoqing G., Imelda M-U., Anil K.S., Peng H., and Jinsong L.. Interleukin-1β Promotes Ovarian Tumorigenesis through a p53/NF-κB-Mediated Inflammatory Response in Stromal Fibroblasts // Neoplasia. – 2013. – Vol. 15. – №4. – P. 409-420.
17. Jacobs M.D., Harrison S.C. Structure of an IκBα/ NF-κB complex // Cell. – 1998. – Vol. 95. – №6. – P. 749-758.
18. Jagetia G.C., Aggarwal B.B. "Spicing up" of the immune system by curcumin // J. Clin. Immunol. – 2007. – Vol. 27. – P. 19-35.
19. Kalgutkar A.S., Zhao Z. Discovery and design of selective cyclooxygenase-2 inhibitors as non- ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents //Curr. Drug Targets. – 2001. – Vol. 2. – P. 79-106.
20. Karin M., Lin A. NF-kappaB at the crossroads of life and death //Nat.Immunol.– 2002. – Vol. 3. – №3. – P. 221-227.
21. Klotz T., Bloch W., Jacobs G., Niggemann S., Engelmann U., Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer // Urology. – 1999. – Vol. 54. – P. 416-419.
22. Korkaya H., Paulson A., Iovino F., Wicha M.S.: HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion // Oncogene. – 2008. – Vol. 27. – P. 6120-6130.
23. Kouroukis C.T., Baldassarre F.G., Haynes A.E., Imrie K., Reece D.E., Cheung M.C. Bortezomib in Multiple Myeloma: A Practice Guideline // Clin. Oncol. (R. Coll. Radiol). – 2013. – Vol. 13. – P. 463-469.
24. Kwon O., Kim K., He L., Jung M., Jeong S., Ahn J.,Kim B. Complex formation of p65/RelA with nuclear Akt1 for enhanced transcriptional activation of NF-kappaB // Biochem. Biophys Res. Commun. – 2008. – Vol. 365.– P. 771-776.
25. Lee C.H., Jeon Y.T., Kim S.H., Song Y.S. NF-kappaB as a potential molecular target for cancer therapy //Biofactors. – 2007. – Vol. 29. – №1. – P. 19-35.
26. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., Ott G., Muller-Hermelink H.K., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Chan W.C., Staudt L.M. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma // Science. – 2008. – Vol. 319. – P. 1676-1679.
27. Li Q., Verma I.M. NF-κB regulation in the immune system // Nat .Rev.Immunol. – 2002. – Vol. 2. – P. 331-367.
28. Luo J.L., Kamata H., Karin M. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy // J.Clin. Invest. – 2005. – Vol. 115. – P. 2625-2632.
29. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Saito M., Kawagoe J., Takahashi K., Yada-Hashimoto N., Sakata M., Motoyama T., Kurachi H., Tasaka K., Murata Y. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models // J. Biol. Chem. – 2004. – Vol. 279. – №22. – P. 23477-23485.
30. Merkhofer E.C., Cogswell P., Baldwin A.S.: Her2 activates NF-kappa B and induces invasion through the canonical pathway involving IKK alpha // Oncogene. – 2010. – Vol. 29. – P. 1238-1248.
31. Mimeault M., Batra S.K. Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells // Biochim.Biophys.Acta.– 2011. – Vol. 1816. – №1. – P. 25-37.
32. Nakshatri H., Goulet R.J. Jr. NF-kappaB and breast cancer // Curr.Probl. Cancer.– 2002. – Vol. 26. – P. 282-309.
33. Napetschnig J., Wu H. Molecular Basis of NF-κB Signaling // Annual. Review of Biophysics.– 2013. – Vol. 42. – P. 443-468.
34. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept // Nat. Rev. Cancer. – 2012. – Vol. 12. – №2. – P. 133-143.
35. Nikolopoulos S.N., Blaikie P., Yoshioka T., Guo W., Giancotti F.G. Integrin beta4 signaling promotes tumor angiogenesis // Cancer Cell.– 2004. – Vol. 6. – P. 471-483.
36. Noguchi Y., Makino T., Yoshikawa T., Nomura K., Fukuzawa K., Matsumoto A., Yamada T. The possible role of TNF-alpha and IL-2 in inducing tumor-associated metabolic alterations // Surg. Today. – 1996. – Vol. 26. – P.36-41.
37. Peng Y., Power M., Li B., Lin T. Inhibition of IKK down-regulates antigen + Ig E-induced TNF production by mast cells: a role for the IKK-IkappaB-NF-kappaB pathway in IgE-dependent mast cell activation // J. Leukoc. Biol.– 2005. – Vol. 77. – P. 975-983.
38. Pianetti S., Arsura M., Romieu-Mourez R., Cof-fey R.J., Sonenshein G.E. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN // Oncogene. – 2001. – Vol. 20. – P. 1287-1299.
39. Rajasekhar V.K., Studer L., Gerald W., Socci N.D., Scher H.I. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signaling // Nat.Commun.– 2011. – Vol. 2. – P. 162.
40. Robert C. Bast Jr., Bryan Hennessy, and Gor-don B. Mills The biology of ovarian cancer: new opportunities for translation // Nat. Rev. Cancer. – 2009. – Vol. 9. – №6. – P. 415.
41. Samanta A.K., Huang H.J., Bast R.C. Jr., Liao W.S. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB // J. Biol. Chem. – 2004. – Vol. 279. – №9. – P. 7576-7583.
42. Sethi G., Ahn K.S., Xia D., Kurie J.M., Aggarwal B.B. Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene products // J.Immunol. – 2007. – Vol. 179. – P. 1926-1933.
43. Sinn D.I., Lee S.T., Chu K., Jung K.H., et al.Roh J.K. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib //Neuro sci. Res.– 2007. – Vol. 58. – P. 12-18.
44. Sorriento D., Illario M., Finelli R., Iaccarino G. To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator // Transl.Med.UniSa. – 2012. – Vol. 4. – P. 73-85.
45. Suh J., Payvandi F., Edelstein L.C., Amenta P.S., Zong W.X., Geґlinas C., Rabson A.B. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells // Prostate. – 2002. – Vol. 52. – P. 183-200.
46. Suh J., Rabson A.B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? // J. Cell Biochem. – 2004. – Vol. 91. – №1. – P. 100-117.
47. Wilson W. III, Baldwin A.S. Maintenance of constitutive IkappaB kinase activity by glycogen syn-thase kinase-3alpha/beta in pancreatic cancer // Cancer Res. – 2008. – Vol. 68. – P. 8156-8163.
48. Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer // Endocr.Relat. Cancer. – 2005. – Vol. 12. – №1. – P. 37-46.
Review
For citations:
Umezawa K., Gantsev Sh.Kh., Kzyrgalin Sh.R., Yamidanov R.S., Gantsev K.Sh., Amirov R.A., Loginova M.V. THE TRANSCRIPTION FACTOR NF-KB AS A THERAPEUTIC TARGET IN THE TREATMENT OF MALIGNANT TUMORS. Creative surgery and oncology. 2014;(4):69-75. (In Russ.) https://doi.org/10.24060/2076-3093-2014-0-4-69-75
Views:
1146
Email this article 